No supplier or customer ties in IMUX's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Nothing on the wire mentions IMUX yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How IMUX has moved on past release days vs its typical ±3.6% day, and how often it closed up. Computed from daily closes — not a forecast.